FDA's Third-Party Review Program: Quick Review Times, Low Volume
This article was originally published in The Gray Sheet
Executive Summary
Third-party 510(k) submissions are gaining FDA clearance at over three times the rate of comparable submissions made directly to the agency, Eric Rechen, a staffer in FDA's Office of Device Evaluation, said.
You may also be interested in...
In-Vitro Diagnostics Should Be Eligible For Third-Party Review - Industry
FDA should identify more in-vitro diagnostics for inclusion in the agency's "Accredited Persons" third-party premarket review program, DiaSorin VP Regulatory Affairs and Quality Systems, Judith Smith recommended.
In-Vitro Diagnostics Should Be Eligible For Third-Party Review - Industry
FDA should identify more in-vitro diagnostics for inclusion in the agency's "Accredited Persons" third-party premarket review program, DiaSorin VP Regulatory Affairs and Quality Systems, Judith Smith recommended.
FDA Committed To Third-Party Review, Henney Tells Senate HELP Committee
FDA Commissioner Jane Henney is "puzzled" about the low utilization rate within the device industry of the agency's "Accredited Persons" third-party premarket review program, she said at an Oct. 21 Senate Health, Education, Labor and Pensions Committee hearing.